[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019 Herpes Labialis (Oral Herpes) R&D Pipeline Drugs, Companies, Trials and Developments

March 2019 | 50 pages | ID: 29C86DE0511EN
VPAResearch

US$ 2,199.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global demand for Herpes Labialis (Oral Herpes) treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Herpes Labialis (Oral Herpes) are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Herpes Labialis (Oral Herpes) pipeline companies from advancing their products.
Herpes Labialis (Oral Herpes) Report Description
The H1-2019 pipeline review report on Herpes Labialis (Oral Herpes) is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Herpes Labialis (Oral Herpes) pipeline guide presents information on all active drugs currently being developed for Herpes Labialis (Oral Herpes). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Herpes Labialis (Oral Herpes) pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Herpes Labialis (Oral Herpes) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Herpes Labialis (Oral Herpes) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Herpes Labialis (Oral Herpes) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Herpes Labialis (Oral Herpes) pipeline report includes-
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
    • For each pipeline product, the following details are provided-
    • Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
    • Current status of development
    • Drug overview
    • Mechanism of Action
    • Pre-clinical and Clinical Trials
REASONS TO BUY
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Herpes Labialis (Oral Herpes) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Herpes Labialis (Oral Herpes) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Herpes Labialis (Oral Herpes) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
GLOBAL HERPES LABIALIS (ORAL HERPES) PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Herpes Labialis (Oral Herpes) Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Herpes Labialis (Oral Herpes) pipeline, H1@2019
Mechanism of Action wise Herpes Labialis (Oral Herpes) Pipeline Candidates

AICURIS GMBH & CO KG HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

BEECH TREE LABS INC HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

BRANDENBURG ANTIINFEKTIVA GMBH HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

DOBECURE SL HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

NANOVIRICIDES INC HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

PROVENTION BIO INC HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

S.I.S SHULOV INNOVATIVE SCIENCE LTD HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

SQUAREX LLC HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

VIRONOVA MEDICAL AB HERPES LABIALIS (ORAL HERPES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LATEST HERPES LABIALIS (ORAL HERPES) DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us
Sources and Methodology
Contact Information


More Publications